A

Agilent is a high-quality lab-instruments franchise that just returned to growth: FY2025 revenue of $6.95B was up 6.7% — the first real reacceleration after the FY2023-24 plateau (revenue actually fell from $6.83B to $6.51B before recovering). The MD&A confirms growth was broad-based across all three segments under the new structure (Life Sciences & Diagnostics +11%) and all geographies, with the BIOVECTRA acquisition contributing roughly 2 points. Profitability remains best-in-class for the category: 21.3% operating margin, 18.8% net margin, 19.3% ROE, and the balance sheet strengthened materially with cash up 34.6% to $1.79B and long-term debt down 8.8% to $3.05B. Liabilities/equity of 0.89x and equity up 14.3% reinforce that this is a fortress operator, not a stretched one.

The problem is that the operating result is less clean than the headline. Operating income actually fell 0.6% on 6.7% revenue growth — margin compression is real, and management's own MD&A names the culprit: "recent tariff changes adversely impacted our costs of revenue beginning in the second half of fiscal year 2025." They expect to "substantially mitigate" this in FY2026 via supply chain, pricing and cost actions, but the language is hedged ("timing, amount, scope and nature" all uncertain) and operating cash flow already dropped 11% to $1.56B while capex rose 7.7% — free cash flow generation is going the wrong way at exactly the moment the multiple needs it to expand.